References
- Smith SMG, Judge HM, Peters G, Storey RF. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary interven- tion. Platelets 2004;15:465–474.
- Bode AP, Hickerson DH. Characterization and quantitation by flow cytometry of membranous microparticles formed during activation of platelet suspensions with ionophore or thrombin. Platelets 2000;11:259–271.
- Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335–1338.
- Mitsios JV, Papathanasiou AI, Elisaf M, et al. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin for five weeks in patients with acute coronary syndromes. Platelets 2005;in press.
- Piorkowski M, Weikert U, Schwimmbeck P-L, et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atrovastatin. Thromb Haemost 2004;92:614–620.
- Saw J, Steinhubl SR, Berger PB, et al. Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical inter- action from secondary analysis of a randomized, placebo- controlled clopidogrel trial. Circulation 2003;108:921–924.
- Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. American Journal of Cardiology 2003;92:285–288.
- Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004;350:1495–1504.
- Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32–37.
- Neubauer H, Gu¨ nesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. European Heart Journal 2003;24:1744–1749.
- Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metabolism & Disposition 2003;31:53–59.